These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15311726)

  • 21. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management.
    Boden WE
    Curr Opin Cardiol; 2003 Jul; 18(4):278-85. PubMed ID: 12858126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II.
    Gitt AK; Lautsch D; Ferrières J; De Ferrari GM; Vyas A; Baxter CA; Bash LD; Ashton V; Horack M; Almahmeed W; Chiang FT; Poh KK; Brudi P; Ambegaonkar B
    Atherosclerosis; 2017 Nov; 266():158-166. PubMed ID: 29028484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Failure to achieve recommended LDL cholesterol levels by suboptimal statin therapy relates to elevated cardiac event rates.
    Baessler A; Fischer M; Huf V; Mell S; Hengstenberg C; Mayer B; Holmer S; Riegger G; Schunkert H
    Int J Cardiol; 2005 May; 101(2):293-8. PubMed ID: 15882678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study.
    Faergeman O; Hill L; Windler E; Wiklund O; Asmar R; Duffield E; Sosef F;
    Cardiology; 2008; 111(4):219-28. PubMed ID: 18434729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study.
    Kim HS; Wu Y; Lin SJ; Deerochanawong C; Zambahari R; Zhao L; Zhang Q; Yan P
    Curr Med Res Opin; 2008 Jul; 24(7):1951-63. PubMed ID: 18547466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The safety of aggressive statin therapy: how much can low-density lipoprotein cholesterol be lowered?
    Jacobson TA
    Mayo Clin Proc; 2006 Sep; 81(9):1225-31. PubMed ID: 16970219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
    Duvall WL; Blazing MA; Saxena S; Guyton JR
    J Cardiovasc Risk; 2002 Dec; 9(6):339-47. PubMed ID: 12478203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study.
    Ballantyne CM; Hoogeveen RC; Raya JL; Cain VA; Palmer MK; Karlson BW;
    Atherosclerosis; 2014 Jan; 232(1):86-93. PubMed ID: 24401221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Lipid-lowering therapy and patient adherence in the MULTI GAP 2013 trial].
    Simonyi G
    Orv Hetil; 2014 Apr; 155(17):669-75. PubMed ID: 24755449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
    Pearson TA; Denke MA; McBride PE; Battisti WP; Brady WE; Palmisano J
    Mayo Clin Proc; 2005 May; 80(5):587-95. PubMed ID: 15887425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study.
    Van Ganse E; Laforest L; Alemao E; Davies G; Gutkin S; Yin D
    Curr Med Res Opin; 2005 Sep; 21(9):1389-99. PubMed ID: 16197657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia.
    Davidson MH; Donovan JM; Misir S; Jones MR
    Am J Cardiovasc Drugs; 2010; 10(5):305-14. PubMed ID: 20860413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
    Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
    J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
    Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
    Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Second-line treatments for dyslipidemia in patients at risk of cardiovascular disease.
    Kondo Y; Hamai J; Nezu U; Shigematsu E; Kamiko K; Yamazaki S; Yoshii T; Takahashi M; Takano T; Kawasaki S; Yamada M; Yamakawa T; Terauchi Y
    Endocr J; 2014; 61(4):343-51. PubMed ID: 24452015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The nurse practitioner's role in helping patients achieve lipid goals with statin therapy.
    Mason CM
    J Am Acad Nurse Pract; 2005 Jul; 17(7):256-62. PubMed ID: 15982245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacotherapy of dyslipidemia.
    McKenney JM
    Cardiovasc Drugs Ther; 2001 Sep; 15(5):413-22. PubMed ID: 11855660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination therapy in dyslipidemia: where are we now?
    Catapano AL; Farnier M; Foody JM; Toth PP; Tomassini JE; Brudi P; Tershakovec AM
    Atherosclerosis; 2014 Nov; 237(1):319-35. PubMed ID: 25299967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.